Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Can-Fite BioPharma ( (CANF) ).
On May 18, 2026, Can-Fite BioPharma and Vetbiolix reported that a peer-reviewed article in Frontiers in Veterinary Science described positive study results for Piclidenoson in dogs with osteoarthritis. The oral A3 adenosine receptor agonist significantly improved mobility and pain scores, including LOAD and VAS measures, while showing no serious treatment-related adverse events, supporting its profile as a potential disease-modifying oral therapy for canine osteoarthritis.
Piclidenoson is licensed to Vetbiolix for veterinary use under an agreement potentially worth up to $325 million in upfront, milestone, and royalty payments, with an advanced Phase 2 trial in canine osteoarthritis currently under way. The publication is presented by Can-Fite as external validation that could strengthen the commercial prospects of its Vetbiolix partnership and extend the reach of its A3AR technology into the multi-billion-dollar companion animal osteoarthritis market, potentially enhancing long-term revenue diversification beyond human indications.
The most recent analyst rating on (CANF) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, ongoing losses, and persistent cash burn) and bearish technical signals (price below key moving averages with negative MACD). Low leverage provides some risk mitigation, but valuation is not supportive given losses and no dividend data.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is an advanced clinical-stage biotechnology company developing proprietary small-molecule drugs targeting multi-billion-dollar markets in cancer, liver, and inflammatory diseases. Its lead candidate Piclidenoson is in Phase 3 trials for psoriasis, while Namodenoson is in late-stage studies for hepatocellular carcinoma, MASH, and pancreatic cancer, and CF602 is being developed for erectile dysfunction, all supported by safety data from more than 1,600 patients.
The company’s platform focuses on A3 adenosine receptor agonists and related mechanisms, with Namodenoson holding Orphan Drug Designation in the U.S. and Europe and Fast Track status for second-line hepatocellular carcinoma from the U.S. Food and Drug Administration. This portfolio positions Can-Fite as a niche player in immuno-oncology and inflammatory indications, aiming to monetize assets through partnerships and licenses across human and veterinary markets.
Average Trading Volume: 1,166,930
Technical Sentiment Signal: Sell
Current Market Cap: $7.62M
See more data about CANF stock on TipRanks’ Stock Analysis page.